MedTrace Logo

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

NCT06786312 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-01-22

No results posted yet for this study

Summary

To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

Apatinib

250mg, P.O, qd, 21 days per cycle;

DRUG

Adebrelimab

20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;

DRUG

Etoposide Injection

100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.

DRUG

Carboplatin Injection

Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-25
Primary Completion
2027-07-25
Completion
2028-09-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786312 on ClinicalTrials.gov